Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정성현 | - |
dc.contributor.author | 김석진 | - |
dc.contributor.author | 윤덕현 | - |
dc.contributor.author | 박용 | - |
dc.contributor.author | 강혜진 | - |
dc.contributor.author | 고영일 | - |
dc.contributor.author | 이경원 | - |
dc.contributor.author | 이원식 | - |
dc.contributor.author | 양덕환 | - |
dc.contributor.author | 도영록 | - |
dc.contributor.author | 김민경 | - |
dc.contributor.author | 유쾌한 | - |
dc.contributor.author | 최윤석 | - |
dc.contributor.author | 윤환정 | - |
dc.contributor.author | 이준호 | - |
dc.contributor.author | 조재철 | - |
dc.contributor.author | 엄현석 | - |
dc.contributor.author | 곽재용 | - |
dc.contributor.author | 신호진 | - |
dc.contributor.author | 박병배 | - |
dc.contributor.author | 현신영 | - |
dc.contributor.author | 이성윤 | - |
dc.contributor.author | 권지현 | - |
dc.contributor.author | 오성용 | - |
dc.contributor.author | 김효정 | - |
dc.contributor.author | 손병석 | - |
dc.contributor.author | 원종호 | - |
dc.contributor.author | 김세형 | - |
dc.contributor.author | 이호섭 | - |
dc.contributor.author | 서철원 | - |
dc.contributor.author | 김원석 | - |
dc.date.accessioned | 2023-01-17T12:40:28Z | - |
dc.date.available | 2023-01-17T12:40:28Z | - |
dc.date.created | 2022-10-17 | - |
dc.date.issued | 2022-10 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/86622 | - |
dc.description.abstract | PurposeFebrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). Materials and methodsWe conducted a prospective cohort study to evaluate the effectiveness of pegfilgrastim prophylaxis in DLBCL patients receiving R-CHOP, and we compared them with the PROCESS cohort (n=485). ResultsSince January 2015, 986 patients with DLBCL were enrolled. Pegfilgrastim was administered at least once in 930 patients (94.3%), covering 90.3% of all cycles. FN developed in 137 patients (13.9%) in this cohort (23.7% in the PROCESS cohort, p<0.001), and 4.2% of all cycles (10.2% in the PROCESS cohort, p<0.001). Dose delay was less common (≥3 days: 18.1% vs. 23.7%, p=0.015; ≥5 days: 12.0% vs. 18.3%, p=0.023) in this cohort than in the PROCESS cohort. The incidence of TRM (3.2% vs. 5.6%, p=0.047) and infection-related death (1.8% vs. 4.5%, p=0.004) was lower in this cohort than in the PROCESS cohort. The 4-year overall survival (OS) and progression-free survival (PFS) rates of the two cohorts were not different (OS: 73.0% vs. 71.9%, p=0.545; PFS: 69.5% vs. 68.8%, p=0.616). However, in patients aged ≥75 years, the 4-year OS and PFS rates were higher in this cohort than in the PROCESS cohort (OS: 49.6% vs. 33.7%, p=0.032; PFS: 44.2% vs. 30.3% p=0.047). Conclusion Pegfilgrastim prophylaxis is effective in the prevention of FN and infection-related death in DLBCL patients receiving R-CHOP, and it also improves OS in patients aged ≥75 years. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한암학회 | - |
dc.relation.isPartOf | Cancer Research and Treatment | - |
dc.title | Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000891831900031 | - |
dc.identifier.doi | 10.4143/crt.2021.1168 | - |
dc.identifier.bibliographicCitation | Cancer Research and Treatment, v.54, no.4, pp.1268 - 1277 | - |
dc.identifier.kciid | ART002886615 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85140144665 | - |
dc.citation.endPage | 1277 | - |
dc.citation.startPage | 1268 | - |
dc.citation.title | Cancer Research and Treatment | - |
dc.citation.volume | 54 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | 유쾌한 | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Pegfilgrastim | - |
dc.subject.keywordAuthor | Prophylaxis | - |
dc.subject.keywordAuthor | Diffuse large B-cell lymphoma | - |
dc.subject.keywordPlus | RECEIVING CHEMOTHERAPY | - |
dc.subject.keywordPlus | ELDERLY-PATIENTS | - |
dc.subject.keywordPlus | DOSE INTENSITY | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | FILGRASTIM | - |
dc.subject.keywordPlus | RITUXIMAB | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | HODGKIN | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.